BAJAJ BROKING

Notification close image
No new Notification messages
card image
🚨 TRADING HOLIDAY 🚨
The NSE and BSE will remain closed for trading and settlement on Wednesday, August 27, 2025, on account of Ganesh Chaturthi.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524636

OXYGENTAPH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

OXYGENTA PHARMACEUTICAL LIMITE Share Price Update

As of the latest trading session, OXYGENTA PHARMACEUTICAL LIMITE share price is currently at ₹ 81, which is up by ₹ 0.05 from its previous closing. Today, the stock has fluctuated between ₹ 77.00 and ₹ 82.00. Over the past year, OXYGENTA PHARMACEUTICAL LIMITE has achieved a return of 107.72 %. In the last month alone, the return has been -22.90 %. Read More...

Investment Returns

Over 1 Month -22.90% Over 3 Months -9.53% Over 6 Months 3.78% Over 1 Year 107.72%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

OXYGENTA PHARMACEUTICAL LIMITE fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    299.60

  • P/E Ratio (TTM)

    -19.89

  • Beta

    0.71

  • Book Value / share

    -6.93

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    -6.11

info icon alternate text

OXYGENTA PHARMACEUTICAL LIMITE Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 15.13
Operating Expense 23.43
Net Profit -6.11
Net Profit Margin (%) -40.38
Earnings Per Share (EPS) -1.65
EBITDA -6.67
Effective Tax Rate (%) 25.03
Particulars MAR 2025 (Values in Cr)
Revenue 49.47
Operating Expense 53.05
Net Profit -2.15
Net Profit Margin (%) -4.34
Earnings Per Share (EPS) -0.60
EBITDA -1.90
Effective Tax Rate (%) 43.42
Particulars DEC 2024 (Values in Cr)
Revenue 33.21
Operating Expense 38.66
Net Profit -3.93
Net Profit Margin (%) -11.83
Earnings Per Share (EPS) 1.07
EBITDA -3.86
Effective Tax Rate (%) 20.76
Particulars SEP 2024 (Values in Cr)
Revenue 14.01
Operating Expense 17.53
Net Profit -2.85
Net Profit Margin (%) -20.34
Earnings Per Share (EPS) -0.81
EBITDA -1.42
Effective Tax Rate (%) -2.88
Particulars JUN 2024 (Values in Cr)
Revenue 12.62
Operating Expense 15.46
Net Profit -1.36
Net Profit Margin (%) -10.77
Earnings Per Share (EPS) -0.39
EBITDA -1.75
Effective Tax Rate (%) 51.41
Particulars MAR 2025 (Values in Cr)
Revenue 109.30
Operating Expense 124.69
Net Profit -10.30
Net Profit Margin (%) -9.42
Earnings Per Share (EPS) -2.86
EBITDA -8.96
Effective Tax Rate (%) 28.22
Particulars MAR 2024 (Values in Cr)
Revenue 39.64
Operating Expense 53.59
Net Profit -3.48
Net Profit Margin (%) -8.77
Earnings Per Share (EPS) -1.09
EBITDA -9.62
Effective Tax Rate (%) 74.90
Particulars MAR 2023 (Values in Cr)
Revenue 30.99
Operating Expense 41.65
Net Profit -11.57
Net Profit Margin (%) -37.33
Earnings Per Share (EPS) -6.36
EBITDA -7.82
Effective Tax Rate (%) -1.75
Particulars MAR 2022 (Values in Cr)
Revenue 60.52
Operating Expense 61.56
Net Profit -0.61
Net Profit Margin (%) -1.00
Earnings Per Share (EPS) -0.48
EBITDA 2.02
Effective Tax Rate (%) -24.48
Particulars MAR 2021 (Values in Cr)
Revenue 52.03
Operating Expense 51.18
Net Profit 2.93
Net Profit Margin (%) 5.63
Earnings Per Share (EPS) 2.87
EBITDA 6.11
Effective Tax Rate (%) 6.38
Particulars MAR 2024 (Values in Cr)
Book Value / Share -6.18
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -24.27
Particulars MAR 2023 (Values in Cr)
Book Value / Share -32.53
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -25.27
Particulars MAR 2022 (Values in Cr)
Book Value / Share -24.38
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 2.43
Particulars MAR 2021 (Values in Cr)
Book Value / Share -37.27
ROE % -5.79
ROCE % 7.89
Total Debt to Total Equity 0.00
EBITDA Margin 7.55
Particulars MAR 2020 (Values in Cr)
Book Value / Share -40.14
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -57.14
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 63.19
Total Liabilities 63.19
Total Equity -20.12
Share Outstanding 33483500
Price to Book Ratio -4.69
Return on Assets (%) -5.50
Return on Capital (%) -9.38
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 54.26
Total Liabilities 54.26
Total Equity -46.20
Share Outstanding 14201300
Price to Book Ratio -1.13
Return on Assets (%) -21.32
Return on Capital (%) -53.09
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.15
Total Assets 31.17
Total Liabilities 31.17
Total Equity -34.62
Share Outstanding 14201300
Price to Book Ratio -0.99
Return on Assets (%) -1.95
Return on Capital (%) -3.49
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.44
Total Assets 33.86
Total Liabilities 33.86
Total Equity -38.01
Share Outstanding 10201300
Price to Book Ratio 0.00
Return on Assets (%) 8.65
Return on Capital (%) 29.69
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 18.62
Total Liabilities 18.62
Total Equity -40.94
Share Outstanding 10201300
Price to Book Ratio 0.00
Return on Assets (%) -31.08
Return on Capital (%) 38.56
Particulars MAR 2024 (Values in Cr)
Net Income -13.87
Cash from Operations -13.04
Cash from Investing -4.08
Cash from Financing 17.13
Net change in Cash 0.00
Free Cash Flow -8.94
Particulars MAR 2023 (Values in Cr)
Net Income -11.37
Cash from Operations -1.63
Cash from Investing -9.63
Cash from Financing 11.22
Net change in Cash -0.04
Free Cash Flow 8.01
Particulars MAR 2022 (Values in Cr)
Net Income -0.48
Cash from Operations -1.55
Cash from Investing -4.94
Cash from Financing 6.33
Net change in Cash -0.28
Free Cash Flow 3.38
Particulars MAR 2021 (Values in Cr)
Net Income 3.14
Cash from Operations -1.40
Cash from Investing -6.71
Cash from Financing 8.66
Net change in Cash 0.32
Free Cash Flow 5.33
Particulars MAR 2020 (Values in Cr)
Net Income -5.94
Cash from Operations -2.74
Cash from Investing -0.49
Cash from Financing 3.18
Net change in Cash 0.09
Free Cash Flow -2.22
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 13.59 1.82 255.19 30.00 / 69.75
BLISS GVS PHARMA LTD 159.00 15.73 1.59 1677.41 105.05 / 190.65
CIPLA LTD 1601.10 23.98 4.14 129329.50 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 323.75 9.12 2.62 952.83 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2799.20 50.08 24.30 47420.14 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 18.10 5.26 255.19 30.00 / 69.75
AMRUTAJAN HEALTH LTD 708.10 37.55 6.26 2047.16 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8297.10 98.09 26.92 20742.75 6222.35 / 10653.05
BLISS GVS PHARMA LTD 159.00 23.77 1.58 1677.41 105.05 / 190.65

OXYGENTA PHARMACEUTICAL LIMITE Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
81.00 0.06 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 82.40
  • 26 Days 94.70
  • 10 Days 86.10
  • 50 Days 99.10
  • 12 Days 87.50
  • 100 Days 97.40
  • 20 Days 92.20
  • 200 Days 88.80
79.98 PIVOT

First Support

77.67

First Resistance

83.27

Second Support

74.38

Second Resistance

85.58

Third Support

72.07

Third Resistance

88.87

RSI

23.38

ADX

56.24

MACD

-7.24

Williams % R

-84.14

Commodity Channel Index (CCI)

-126.78

Date

2025-08-25

Week

8457.00

Same Day

2612.00

Month

5408.00

1 Year

0.72

3 Year

0.37

Over 1 Month

-22.90%

down

Over 1 Year

107.72%

down

Over 3 Months

-9.53%

down

Over 3 Years

43.40%

down

Over 6 Months

3.78%

down

Over 5 Years

53.27%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

OXYGENTA PHARMACEUTICAL LIMITE shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

OXYGENTA PHARMACEUTICAL LIMITE corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

OXYGENTA PHARMACEUTICAL LIMITE Share Price

Oxygenta Pharmaceutical Limited (Formerly known S S Organics Ltd) was incorporated as Private Limited Company in year 1990 and converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. Later, the Company changed its name from S.S. Organics Ltd. to Oxygenta Pharmaceutical Limited in 2021-22.

The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs. The Company is doing contract manufacturing work for APL and also having its own production. The Company is engaged in manufacture of bulk drugs. It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs. The Company has plant located at Medak in Andhra Pradesh.

The Company has been doing contract manufacturing work with APL for manufacturing of Cirprofloxacin HCL from Q-Acid and has been manufacturing Pantaprozole Sodium and Gabapentine for own production. To minimize the working capital requirement and to have consistent income, it is necessary to continue contract manufacturing work till the Company gets working capital limits from any Bank. This contract manufacturing helps it to meet major operational expenses of the Company. Since the Company started commercial production in July, 2015 after fire accident, it is in the process of stabilizing the manufacturing and marketing.

Parent organization Indian Private
NSE symbol [-]
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Oxygenta Pharmaceutical Ltd?

Answer Field

Oxygenta Pharmaceutical Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 81.00 as on Aug 26 2025 03:17 PM.

What is the Market Cap of Oxygenta Pharmaceutical Ltd Share?

Answer Field

The market cap of Oxygenta Pharmaceutical Ltd for NSE ₹ 0.00 & for BSE ₹ 299.60 as on Aug 26 2025 03:17 PM.

What is the 52 Week High and Low of Oxygenta Pharmaceutical Ltd?

Answer Field

The 52 Week High and Low of Oxygenta Pharmaceutical Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 133.50 and ₹ 36.21.

What is 1 year return for Oxygenta Pharmaceutical Ltd?

Answer Field

The 1 year returns on the stock has been 107.72%.

What is the P/E Ratio of Oxygenta Pharmaceutical Ltd Share?

Answer Field

As on Aug 26 2025 03:17 PM the price-to-earnings (PE) ratio for Oxygenta Pharmaceutical Ltd share is -19.89.

What is the PB ratio of Oxygenta Pharmaceutical Ltd Share?

Answer Field

As on Aug 26 2025 03:17 PM, the price-to-book (PB) ratio for Oxygenta Pharmaceutical Ltd share is -6.93.

How to Buy Oxygenta Pharmaceutical Ltd Share?

Answer Field

You can trade in Oxygenta Pharmaceutical Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Oxygenta Pharmaceutical Ltd Share on Bajaj Broking App?

Answer Field

To buy Oxygenta Pharmaceutical Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Oxygenta Pharmaceutical Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91